Australia markets closed

UFP Technologies, Inc. (UFPT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
251.00-1.15 (-0.46%)
As of 09:59AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close252.15
Open252.45
Bid244.40 x 100
Ask254.75 x 100
Day's range251.00 - 254.73
52-week range123.68 - 257.29
Volume1,122
Avg. volume63,285
Market cap1.918B
Beta (5Y monthly)0.81
PE ratio (TTM)42.98
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Chimerix Appoints Marc D. Kozin to Board of Directors

    Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effe

  • GlobeNewswire

    UFP Technologies to Present and Host 1X1 Investor Meetings at the KeyBanc Capital Markets 4th Annual Life Sciences and MedTech Investor Forum

    NEWBURYPORT, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT) an Innovative designer and custom manufacturer of components, subassemblies, products, and packaging primarily for the medical market today announced that Chairman and Chief Executive Officer R. Jeffrey Bailly and Chief Financial Officer Ron Lataille will participate in the upcoming KeyBanc Capital Markets 4th Annual Life Sciences and MedTech Investor Forum to be held virtually on March 19 and 20, 2024.

  • GlobeNewswire

    UFP Technologies Announces Record 2023 Results

    NEWBURYPORT, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a designer and custom manufacturer of engineered solutions primarily for the medical market, today reported net income of $44.9 million or $5.83 per diluted common share outstanding for its year ended December 31, 2023, compared to net income of $41.8 million or $5.45 per diluted common share outstanding for 2022. Net sales for 2023 were $400.1 million, 13.1% higher than 2022 sales of $353.8 million. For